Business Context and Reporting Period
Company: Coherus Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 29, 2016
Context: The Company entered into a material definitive agreement to raise capital through a private placement of convertible senior notes. Additionally, the Company issued a press release regarding financial results for the fourth quarter and full year ended December 31, 2015, though the specific numerical data is contained in an exhibit and not detailed in the body of this filing.
Key Financial Metrics and Transaction Details
- Debt Issuance: $100 million aggregate principal amount of 8.2% Convertible Senior Notes due 2022.
- Interest Rate: 8.2% per annum, payable quarterly in arrears starting March 31, 2016.
- Maturity Date: March 31, 2022.
- Conversion Terms: Initial conversion rate of 44.7387 shares per $1,000 principal amount (equivalent to an initial conversion price of $22.35 per share).
- Redemption Premium: 9% of principal amount payable upon maturity, redemption, or repurchase.
- Investors: HealthCare Royalty Partners III, L.P., MX II Associates LLC, KMG Capital Partners, LLC, and KKR Biosimilar L.P.
- Liquidity Impact: Proceeds were received in cash at a purchase price equal to 100% of the principal amount, less certain expenses.
Material Changes and Transaction Mechanics
The primary material change is the creation of a direct financial obligation of $100 million. The Notes are general, senior unsubordinated obligations guaranteed by certain subsidiaries. Key mechanics include:
- Redemption Rights: On or after March 31, 2020, the Company may redeem the Notes if the stock price exceeds 160% of the conversion price for at least 20 trading days within a 30-day period. The redemption price is 109% of the principal plus accrued interest.
- Fundamental Change Repurchase: In the event of a "fundamental change," the Company must offer to repurchase the Notes at 109% of the principal plus accrued interest.
- Registration Rights: The Company granted investors registration rights for the resale of shares issuable upon conversion.
Guidance, Outlook, and Risks
Financial Results: The filing references a press release (Exhibit 99.1) containing Q4 and full-year 2015 results but does not provide specific revenue, profit, or cash flow figures within the text of this 8-K. Investors must refer to the attached exhibit for operational metrics.
Risks and Contingencies:
- Dilution Risk: Conversion of the Notes into common stock will dilute existing shareholders.
- Default Risk: The Notes are subject to customary events of default, which could trigger immediate payment of all outstanding amounts.
- Market Conditions: The Company's ability to redeem the Notes is contingent on the trading price of its common stock exceeding specific thresholds.
Investor Verification Checklist
- Verify the specific Q4 and full-year 2015 financial results in Exhibit 99.1 (Press Release), as they are not detailed in the main text.
- Review the full Convertible Note Purchase Agreement (Exhibit 10.1) for detailed covenants, adjustment mechanisms for the conversion price, and definitions of "fundamental change."
- Assess the impact of the 8.2% interest rate and the 9% maturity premium on the Company's future cash flow and debt service obligations.
- Confirm the current trading price of Coherus common stock relative to the $22.35 conversion price to evaluate immediate conversion incentives.